This comes a couple of days after all major producers of the medicine cut prices of the injection last week, with Cadila selling it at the lowest price point of Rs 899 per injection compared with Rs 2,400 per dose earlier. Cipla
cut the price from Rs 4,000 per dose to Rs 3,000 per dose.
Given the shortage of supplies, the Union government last week banned the export of Remdesivir. The Drug Controller General of India
approved the emergency use of Remdesivir on June 1, 2020.
Remdesivir is one of the drugs used for treating the SARS-CoV-2 virus in hospitalised adults. As the number of Covid-19 cases shot up in April in the country, severe Remdesivir shortage is being reported in the country, after which Cipla, Mylan, Dr Reddy’s Laboratories, Hetero Healthcare, Jubilant Generics, and Zydus Cadila
got permission to produce and supply the drug in India, a generic version of the original drud by Gilead Life Sciences under voluntary licence.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.